The Sapienza University of Rome, also called simply Sapienza or the University of Rome, and formally the Università degli Studi di Roma "La Sapienza", is a public research university located in Rome, Italy. It is one of the largest European universities by enrollments and one of the oldest in history, founded in 1303.

During the past decade, Sapienza University conducted 65 clinical trials. In the 10-year time frame, 65 clinical trials started and 8 clinical trials were completed, i.e. on average, 12.3% percent of trials that started reached the finish line to date. In the past 5 years, 22 clinical trials started and 5 clinical trials were completed. i.e. 22.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sapienza University" #1 sponsor was "University of Roma La Sapienza" with 48 trials, followed by "Incyte Corporation" with 4 trials sponsored, "Celgene" with 3 trials sponsored, "Campus Bio-Medico University" with 2 trials sponsored and "Emory University" with 2 trials sponsored. Other sponsors include 41 different institutions and companies that sponsored additional 48 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sapienza University" #1 collaborator was "University of Roma La Sapienza" with 10 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 3 trials as a collaborator, "Burdenko Neurosurgery Institute" with 2 trials as a collaborator, "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 1 trials as a collaborator and "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator. Other collaborators include 72 different institutions and companies that were collaborators in the rest 82 trials.

According to Clinical.Site data, the most researched conditions in "Sapienza University" are "Coronary Artery Disease" (13 trials), "Multiple Myeloma" (4 trials), "Arterial Hypertension" (3 trials), "Lymphoma" (3 trials) and "Obesity" (3 trials). Many other conditions were trialed in "Sapienza University" in a lesser frequency.

Most popular intervention types in "Sapienza University" are "Drug" (49 trials), "Other" (9 trials), "Procedure" (9 trials), "Dietary Supplement" (8 trials) and "Device" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Atorvastatin" (3 trials), "Parsaclisib" (3 trials), "Rosuvastatin" (3 trials) and "Dexamethasone" (2 trials). Other intervention names were less common.

The vast majority of trials in "Sapienza University" are 99 trials for "All" genders, 3 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Sapienza University". 1 are not yet recruiting, 14 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 45 completed trials in Sapienza University, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Sapienza University, 3 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 27 trials, and there were also 23 trials that are defined as “Not Applicable".